NYXH | Nyxoah S.A. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.81 - 6.20
52 Week Range	5.55 - 12.21
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	68,351
Average Volume	131,229
Shares Outstanding	34,386,800
Market Cap	211,134,952
Sector	Healthcare
Industry	Medical - Instruments & Supplies
IPO Date	2021-04-28

Valuation
Profitability
Growth
Health
P/E Ratio	-3.00
Forward P/E Ratio	N/A
EPS	-2.05
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	146
Country	Belgium
Website	NYXH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

NYXH's peers: NXGL, MLSS, PDEX, INFU, KRMD, ZJYL, DXR, LMAT, UTMD, MMSI, ATRC, PLSE, POAI, MHUA

*Chart delayed

Analyzing fundamentals for NYXH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see NYXH Fundamentals page.

Watching at NYXH technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NYXH Technicals page.